The assumption that Piezo1 modulation will selectively benefit antitumor immunity is flawed, as Piezo1 is frequently upregulated in various cancer types, where its activation promotes proliferation, invasion, and chemoresistance (128). Here, PIEZO1 is linked to cancer.